Stieh, D. J., Callewaert, K., Sarnecki, M., Hendriks, J., Nijs, S., Euler, Z., … Tomaka, F. L. (2018). Primary Analysis of TRAVERSE: A Phase 1/2a Study to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost HIV Vaccine Regimens. In AIDS RESEARCH AND HUMAN RETROVIRUSES (Vol. 34, pp. 18–18). Madrid, SPAIN: MARY ANN LIEBERT, INC.

Stieh, Daniel J., Katleen Callewaert, Michal Sarnecki, Jenny Hendriks, Steven Nijs, Zelda Euler, Hanneke Schuitemaker, et al. “Primary Analysis of TRAVERSE: A Phase 1/2a Study to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost HIV Vaccine Regimens.” In AIDS RESEARCH AND HUMAN RETROVIRUSES, 34:18–18. MARY ANN LIEBERT, INC, 2018.

Stieh DJ, Callewaert K, Sarnecki M, Hendriks J, Nijs S, Euler Z, et al. Primary Analysis of TRAVERSE: A Phase 1/2a Study to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost HIV Vaccine Regimens. In: AIDS RESEARCH AND HUMAN RETROVIRUSES. MARY ANN LIEBERT, INC; 2018. p. 18–18.

Stieh, Daniel J., et al. “Primary Analysis of TRAVERSE: A Phase 1/2a Study to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost HIV Vaccine Regimens.” AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 34, MARY ANN LIEBERT, INC, 2018, pp. 18–18.

Stieh DJ, Callewaert K, Sarnecki M, Hendriks J, Nijs S, Euler Z, Schuitemaker H, Tomaras GD, Kublin JG, Corey L, McElrath MJ, Ake J, Robb ML, Alter G, Barouch DH, Pau MG, Tomaka FL. Primary Analysis of TRAVERSE: A Phase 1/2a Study to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost HIV Vaccine Regimens. AIDS RESEARCH AND HUMAN RETROVIRUSES. MARY ANN LIEBERT, INC; 2018. p. 18–18.